Showing 15 posts of 381 posts found.


Abbott to acquire Bigfoot Biomedical

September 6, 2023
Business Services Abbott, Bigfoot Biomedical, Diabetes, acquisition, diabetes

Abbott and Bigfoot Biomedical have announced a definitive agreement for Abbott to acquire Bigfoot, however this transaction is still subject …


First cellular therapy for patients with type 1 diabetes approved by FDA

June 29, 2023
Medical Communications Diabetes, FDA, Lantidra, Type 1 diabetes, diabetes

The US Food and Drug Administration (FDA) has announced that it has approved Lantidra, the first allogeneic (donor) pancreatic islet …


AstraZeneca’s Xigduo XR approved in China for adults with type-2 diabetes

June 27, 2023
Medical Communications AstraZeneca, China, Diabetes, Xigduo XR, diabetes

AstraZeneca has announced that its Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily fixed-dose combination, has now been approved …

FDA approves new insulin pump and algorithm software for enhanced automated insulin delivery

May 22, 2023
Medical Communications Devices, FDA, diabetes, insulin

The US Food and Drug Administration (FDA) has announced that it has cleared the Beta Bionics iLet ACE Pump and …

NHS to pilot artificial pancreas for type 1 diabetes

June 17, 2021
NHS, diabetes, insulin, technology, wearable technology

The NHS has announced that artificial pancreases will be available to patients with type 1 diabetes, with up to 1,000 …


Eli Lilly to collaborate with diabetes tech companies on insulin pen

May 10, 2021
Sales and Marketing Eli Lilly, diabetes

Eli Lilly has signed strategic international agreements with four companies – Dexcom, Glooko, myDiabby Healthcare, and Roche – with the …

Arecor receives £2.8m grant for rapid insulin product

March 31, 2021
Research and Development diabetes, insulin

Arecor has announced today that it has received a £2.8 million grant from Innovate UK, to support the Phase II …

ViaCyte and Gore collaborate on new diabetes treatments

March 3, 2021
Research and Development Type 1 diabetes, diabetes, diabetes treatment, gore, viacyte

Clinical stage medicine company ViaCyte have extended their collaboration with materials science organisation Gore to develop new candidates for the …


Eli Lilly’s diabetes drug tirzepatide reduces blood glucose and weight in Phase III trials

February 18, 2021
Eli Lilly, diabetes

Eli Lilly’s tirzepatide led to significant haemoglobin A1C (HbA1C) and body weight reductions from baseline in adults with type 2 …


Lilly’s tirzepatide generates significant reductions in weight and blood sugar in type 2 diabetes patients

December 10, 2020
Research and Development Eli Lilly, diabetes, tirzepatide

Eli Lilly has announced new data for its glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide, showing …


The December 2020 issue of Pharmafocus is available to read free online now!

November 24, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, clinical trials, diabetes, outsourcing

The final 2020 monthly edition of Pharmafocus is available to read for free online now! After a long and theatrical …


Sun Pharma issues recall of its generic diabetes drug in US market

October 12, 2020
Sales and Marketing FDA, diabetes, recall

Sun Pharma is recalling 747 bottles of its generic diabetes drug Riomet ER in the US.This is due to an …


Novo Nordisk launches new Rybelsus pill for type 2 diabetes in the UK

September 2, 2020
Research and Development Novo Nordisk, diabetes, type 2, type 2 diabetes

Novo Nordisk’s new type 2 diabetes treatment Rybelsus is now available for doctors and physicians in the UK to prescribe …


Arthritis drug Abatacept could be used to treat type 1 diabetes

August 11, 2020
Manufacturing and Production diabetes, insulin, tye 1, type 2

People with type 1 diabetes could see their lives extended by the arthritis drug Abatacept, new study finds. Researchers at …


Eli Lilly asks for a $24 million tax break for diabetes care facility expansion in Indianapolis

July 24, 2020
Medical Communications Eli Lilly, Humalog, diabetes, insulin

Insulin manufacturer Eli Lilly has requested a $24 million tax break over the next 10 years as an investment into …

Latest content